Biomarker Panel Now Available for Genome Research

Researchers in genomics and related molecular biology fields will benefit from the introduction into the market of a panel of key biomarkers associated with drug absorption, distribution, metabolism, and excretion (ADME).

The VeraCode ADME Core Panel produced by Illumina, Inc. (San Diego, CA, USA) has been designed to help researchers study genetic predispositions for differential drug response and adverse events. To this end, its panel of biomarkers has been based on those established by pharmaceutical industry experts in the PharmADME Core List.

The VeraCode ADME Core Panel allows for the identification of 184 biomarkers in 34 genes. The dedicated system employs highly specific and streamlined chemistry so that DNA can be genotyped within eight hours with less than two-and-a-half hours of hands-on time. The supporting software offers a convenient user interface that manages user authentication, logs system activity, and automatically translates genotype data into the star nomenclature used by researchers to analyze pharmacogenetic data.

"Understanding genetic variability associated with drug response and disposition is a key step toward the realization of personalized medicine, and the VeraCode ADME Core Panel will help enable this exciting transformation,” said Jay Flatley, president and CEO of Illumina. "With the cost of bringing a new medicine to market now exceeding $1 billion and over $220 billion spent annually on medications in the U.S., it is critical that we look for savings in all stages of drug development. With its emphasis on rapid operation and high-quality data, the VeraCode ADME Core Panel can help bring safe and effective therapies to patients as quickly as possible.”

Related Links:
Illumina, Inc.